This will place in the same category as cocaine and methamphetamines, which means that its distribution will still be tightly restricted, and usage outside of those tight conditions remain a felony.

It also means that he will be making the manufacture and distribution the exclusive purview of big pharma.

It’s actually worse than the status quo, which is not a surprise, “Uncle Joe” has been among the most hardcore of the drug warriors for over 4 decades:

No one person created America’s war on drugs. No individual is responsible for the accompanying manufactured crises of mass incarceration and impoverishment of working class communities of color. But in the same shamed strata as Richard Nixon and Nancy Reagan, in the view of many, you can find Joe Biden, the wobbly 2020 frontrunner and former vice president.

In his 40 years in the Senate, as is now well known, Biden was a key architect of harsh criminal penalties for nonviolent drug users. Undoing much of his own work was one way to make sense of a large part of the criminal justice plan his presidential campaign recently released. Finding a centrist’s safe-and-happy medium on weed in particular, Biden has not embraced legalization—a.k.a. commercialized, recreational pot use—but has claimed to back decriminalization, or removing at least most pot offenses from the criminal justice system.

But Biden is actually pushing a policy that could wreck the growing American weed industry and massively disrupt users’ access to the drug, attorneys, consultants, academics, and entrepreneurs well-versed in US cannabis policy say.

“I view Biden’s plan as a ham-fisted handing over of cannabis to the pharmaceutical industry,” said Gavin Kogan, a California-based cannabis executive and attorney who chairs Grupo Flor, a large, vertically-integrated cannabis firm.

Cannabis is currently listed as a Schedule I controlled substance, the classification intended for drugs with a high potential for abuse and no medical value—a designation contradicted by a 2017 National Academies of Sciences, Engineering, and Medicine review, mocked on a daily basis by dozens of states with medical-use laws, and that even Attorney General William Barr apparently believes is untenable.

Other than cannabis, there are no major state-legal markets for Schedule I drugs. Would making weed Schedule II—intended only for strictly controlled pharmaceutical drugs, and not recreational nor wellness products, the rubrics under which cannabis is often marketed and sold to Americans—make more sense? It might, but here’s the catch: Drugs listed under Schedule II (which include cocaine and methamphetamine as well as prescription opiates like fentanyl) are available legally but only under strict Food and Drug Administration controls. That is, only with a doctor’s prescription, only after a lengthy FDA-overseen approval process that can include years of clinical trials (and then sold only via a licensed pharmacy), and only for limited applications.

In other words, there are no Schedule II drugs grown, processed, and sold in the way cannabis is brought to market in the United States, either—so that label, too, is probably inadequate. More to the point, if strictly enforced to the letter, Biden’s marijuana policy could rip cannabis away from its current producers and sellers and hand over control of commercial weed to corporate interests instead.

“If the federal government actually enforced the CSA [Controlled Substances Act] Schedule II [on cannabis in a Biden administration], then almost all current state-legal activities would be banned and could be shut down,” said Jonathan Caulkins, a professor at Carnegie Mellon University’s Heinz College who has served as co-director of the nonpartisan RAND Corporation’s Drug Policy Research Center.

………

It wasn’t just advocates with skin—financial or otherwise—in the game suggesting Biden’s plan would likely amount to a gift to a few key players. Experts said the impact of the policy, if enacted, was pretty cut-and-dried.

“To the extent that FDA regulation always favors bigger companies that can afford to meet the regulations, then, yes, putting cannabis in Schedule II would be a sort of Big Pharma model,” said David Herzberg, a historian at the University at Buffalo who specializes in drug policy and authored Happy Pills in America: From Miltown to Prozac, a review of how prescription drugs have been developed, marketed, and sold.

………

It’s not clear exactly how Biden hit upon Schedule II as the magic solution, or if he took input from drug-policy reform advocates or cannabis industry players—or took cues instead from the anti-legalization activists working against them. A spokesman for Biden’s campaign did not respond to emails, text messages, or a phone call seeking comment.

“There’s no way this [Biden’s plan] will ever go far enough to remedy the damages these communities of color have suffered,” said Solonje Burnett, co-founder of the Brooklyn-based cannabis brand hub Humble Bloom, adding that his was a “half measure” that put him on “the wrong side of history, again.”

………

“His stance is to blow up 90 percent of the existing regulated and traditional market,” said Sean Donahoe, an Oakland, California-based cannabis-industry consultant. That could be a disruption worse, even, than any George Bush or Barack Obama-era crackdown—when many businesses and operators suffered raids or received threatening letters.

This “shows [Biden’s] fundamental worldview is framed through a corporate lens with no regard for existing operators, nor good public policy,” Donahoe added.

As absurd as it might be to list cannabis in Schedule I, lumping weed with opiates, coke, and pharmaceuticals in Schedule II is also intellectually dishonest, critics said.

………

The proposal would do for cannabis “the same thing it’s done for meth: Ensure reduced research initiatives, selective prosecution, and a thriving black market,” said Michael Backes, a Southern California-based cannabis industry consultant and author of Cannabis Pharmacy: The Practical Guide to Medical Marijuana.

This is classic Biden:  It’s wrong, and favors entrenched and predatory incumbents, just like he did with the credit card industry.